Cystic fibrosis foundation pulmonary guideline pharmacologic approaches to prevention and Eradication of Initial Pseudomonas aeruginosa Infection

Annals of the American Thoracic Society

Volumn 11, Issue 10, 2014, Pages 1640-1650

  Mogayzel, Peter J ^a,m   Naureckas, Edward T ^b   Robinson, Karen A ^a   Brady, Cynthia ^c   Guill, Margaret ^d   Lahiri, Thomas ^e   Lubsch, Lisa ^f   Matsui, Jane ^g   Oermann, Christopher M ^h   Ratjen, Felix ⁱ   Rosenfeld, Margaret ^j   Simon, Richard H ^k   Hazle, Leslie ^l   Sabadosa, Kathy ^l   Marshall, Bruce C ^l   Mueller, Gary ⁿ   Hadjiliadis, Denis ^o   Hoag, Jeffrey B ^p  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e UNIVERSITY OF VERMONT   (United States)

^f SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

^g UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^l CYSTIC FIBROSIS FOUNDATION   (United States)

^m JOHNS HOPKINS HOSPITAL   (United States)

ⁿ WRIGHT STATE UNIVERSITY   (United States)

^o UNIVERSITY OF PENNSYLVANIA   (United States)

^p DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Airway infection; Antipseudomonal vaccine; Bronchoscopy; Inhaled antibiotics; Oropharyngeal culture

Indexed keywords

ANTIBIOTIC AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIUM CULTURE; BRONCHOSCOPY; COCHRANE LIBRARY; CONTROLLED VOCABULARY; CYSTIC FIBROSIS; EMBASE; ERADICATION THERAPY; HUMAN; LUNG LAVAGE; MEDICAL SOCIETY; MEDLINE; PRACTICE GUIDELINE; PSEUDOMONAS INFECTION; REVIEW; SPUTUM; SYSTEMATIC REVIEW; COMPLICATION; MEDICAL RESEARCH; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; BIOMEDICAL RESEARCH; CYSTIC FIBROSIS; HUMANS; PRACTICE GUIDELINES AS TOPIC; PSEUDOMONAS INFECTIONS; SOCIETIES, MEDICAL;

EID: 84920412587     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201404-166OC     Document Type: Review

References (46)

1. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW; Inhaled Tobramycin in Young Children Study Group; Cystic Fibrosis Foundation Therapeutics Development Network. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009;154:183-188.
2. Aebi C, Bracher R, Liechti-Gallati S, Tschäppeler H, Rüdeberg A, Kraemer R. The age at onset of chronic Pseudomonas aeruginosa colonization in cystic fibrosis: Prognostic significance. Eur J Pediatr 1995;154(Suppl 4)S69-S73.
3. Ballmann M, Rabsch P, von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998;53:732-737.
4. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
5. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999;67:4744-4750.
6. Robinson TE, Leung AN, Chen X, Moss RB, Emond MJ. Cystic fibrosis HRCT scores correlate strongly with Pseudomonas infection. Pediatr Pulmonol 2009;44:1107-1117.
7. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33:483-491.
8. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, Molin S. Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: An evolutionary perspective. Nat Rev Microbiol 2012;10: 841-851.
9. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-158.
10. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008;7: 523-530.
11. Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev 2010; 11:177-184.
12. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
13. Mayer-Hamblett N, Kronmal RA, Gibson RL, Rosenfeld M, Retsch- Bogart G, Treggiari MM, Burns JL, Khan U, Ramsey BW, EPIC Investigators. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012;47:125-134.
14. Sawaya GF, Guirguis-Blake J, LeFevre M, Harris R, Petitti D; U.S. Preventive Services Task Force. Update on the methods of the U.S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med 2007;147:871-875.
15. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167: 841-849.
16. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros 2013;12:29-34.
17. Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial. Thorax 2010;65:286-291.
18. Taccetti G, Bianchini E, Cariani L, Buzzetti R, Costantini D, Trevisan F, Zavataro L, Campana S; Italian Group for P. aeruginosa Eradication in Cystic Fibrosis. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: A randomised multicentre study comparing two different protocols. Thorax 2012; 67:853-859.
19. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, et al.; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011;165:847-856.
20. Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-726.
21. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Döring G, von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
22. Tramper-Stranders GA, Wolfs TF, van Haren Noman S, van Aalderen WM, Nagelkerke AF, Nuijsink M, Kimpen JL, van der Ent CK. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010;65:915-920.
23. Döring G, Meisner C, Stern M; Flagella Vaccine Trial Study Group. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci USA 2007;104:11020-11025.
24. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-275.
25. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-452.
26. Ramsey BW, Wentz KR, Smith AL, Richardson M, Williams-Warren J, Hedges DL, Gibson R, Redding GJ, Lent K, Harris K. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-337.
27. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328.
28. Ratjen F, Döring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-984.
29. Tiddens H, DeBoeck C, Clancy JP, Fayon M, Arets B, Bresnik M, Derchak A, Oermann CM. Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa (PA) infection in children with cystic fibrosis (CF): Initial results from a phase 2 study. Pediatr Pulmonol 2013;48:293.
30. Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM, ALPINE study investigators. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. J Cyst Fibros (In press).
31. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;4:CD004197.
32. Döring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012;11:461-479.
33. UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis, 3rd edition. Bomley, Kent, United Kingdom: Cystic Fibrosis Trust; 2009.
34. Kenny SL, Shaw TD, Downey DG, Moore JE, Rendall JC, Elborn JS. Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis. BMJ Open Resp Res 2014;1:e000021.
35. Saiman L, Siegel J; Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24(Suppl)S6-S52.
36. Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: A randomized trial. JAMA 2011;306:163-171.
37. Jain K, Wainwright C, Smyth AR. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database Syst Rev 2013;12: CD009530.
38. Döring G. Vaccine development for patients with cystic fibrosis. Expert Rev Vaccines 2012;11:259-261.
39. Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum Vaccin 2011;7:999-1011.
40. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2013;6:CD001399.
41. Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C. An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 2009;77:1083-1090.
42. Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, Downer VS, Fliege J, Hazle LA, Jain M, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35:S1-S67.
43. Kappler M, Kraxner A, Reinhardt D, Ganster B, Griese M, Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006;61: 684-688.
44. Le Gall F, Le Berre R, Rosec S, Hardy J, Gouriou S, Boisramé-Gastrin S, Vallet S, Rault G, Payan C, Héry-Arnaud G. Proposal of a quantitative PCR-based protocol for an optimal Pseudomonas aeruginosa detection in patients with cystic fibrosis. BMC Microbiol 2013;13:143.
45. Xu J, Moore JE, Murphy PG, Millar BC, Elborn JS. Early detection of Pseudomonas aeruginosa: comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF). Ann Clin Microbiol Antimicrob 2004;3:21.
46. U.S. Preventive Services Task Force. Grade definitions. October 2014 [accessed 2014 Oct]. Available from: http://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions.